Tilray Brands (TLRY) Share-based Compensation (2017 - 2026)
Tilray Brands (TLRY) posted Share-based Compensation of $13.7 million for Q1 2026, up 11.74% on a QoQ basis from $12.3 million in Q4 2025, and up 240.15% year-over-year from $4.0 million in Q1 2025.
Tilray Brands (TLRY) Share-based Compensation (2017 - 2026) Analysis & Trends
Tilray Brands' Share-based Compensation history runs 10 years deep, the most recent figure standing at $13.7 million for Q1 2026.
- Quarterly Share-based Compensation rose 240.15% year-over-year to $13.7 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $37.2 million (up 46.06% YoY) and the FY2025 annual result came in at $24.3 million, down 23.54% from the prior year.
- Share-based Compensation was $13.7 million for Q1 2026 at Tilray Brands, up from $12.3 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $16.5 million in Q4 2023 and bottomed at -$14.5 million in Q1 2022.
- A 5-year average of $5.7 million and a median of $7.1 million in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation plunged 158.87% — and 2023, when it surged 305.62%.
- Tilray Brands' Share-based Compensation stood at -$8.0 million in 2022, then soared by 305.62% to $16.5 million in 2023, then slumped by 56.03% to $7.2 million in 2024, then soared by 69.73% to $12.3 million in 2025, then gained by 11.74% to $13.7 million in 2026.
- Business Quant data shows TLRY's Share-based Compensation at $13.7 million in Q1 2026, $12.3 million in Q4 2025, and $5.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 58.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.00 Mn |
| 10 | Tilray Brands | 465.02 Mn | 373.06 Mn | 54.95 Mn | 13.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 13.73 Mn |
| Feb 28, 2026 | 13.73 Mn |
| Nov 30, 2025 | 12.28 Mn |
| Nov 30, 2025 | 12.28 Mn |
| Aug 31, 2025 | 5.05 Mn |
| Aug 31, 2025 | 5.05 Mn |
| May 31, 2025 | 6.10 Mn |
| May 31, 2025 | 6.10 Mn |
| Feb 28, 2025 | 4.04 Mn |
| Feb 28, 2025 | 4.04 Mn |
| Nov 30, 2024 | 7.24 Mn |
| Nov 30, 2024 | 7.24 Mn |
| Aug 31, 2024 | 6.92 Mn |
| Aug 31, 2024 | 6.92 Mn |
| May 31, 2024 | 7.25 Mn |
| May 31, 2024 | 7.25 Mn |
| Feb 29, 2024 | 8.06 Mn |
| Feb 29, 2024 | 8.06 Mn |
| Nov 30, 2023 | 16.46 Mn |
| Nov 30, 2023 | 16.46 Mn |